{"data":{"id":"us/21-cfr-207.37","jurisdiction":"us","citation":"21 CFR 207.37","heading":"What restrictions pertain to the use of the NDC?","body":"(a) A product may be deemed to be misbranded if an NDC is used:\n(1) To represent a different drug than the drug for which the NDC has been assigned, as described in § 207.33;\n(2) To denote or imply FDA approval of a drug; or\n(3) On products that are not subject to parts 207, 607 of this chapter, or 1271 of this chapter, such as dietary supplements and medical devices.\n(b) If marketing is resumed for a discontinued drug, and no changes have been made to the drug that would require a new NDC under § 207.35, the drug must have the same NDC that was assigned to it as described in § 207.33, before marketing was discontinued.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER C—DRUGS: GENERAL","PART 207—REQUIREMENTS FOR FOREIGN AND DOMESTIC ESTABLISHMENT REGISTRATION AND LISTING FOR HUMAN DRUGS, INCLUDING DRUGS THAT ARE REGULATED UNDER A BIOLOGICS LICENSE APPLICATION, AND ANIMAL DRUGS, AND THE NATIONAL DRUG CODE","Subpart C—National Drug Code"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"cace62dc5997e0952f267409dcef9fc120f2acb182a6784598c2124f6ae2eaf3","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-207.35","next":"us/21-cfr-207.41"},"notice":"GroundRules: Original legal text. Not legal advice."}